StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Palvella Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Palvella Therapeutics's operating margin for the twelve months ending Sep 30, 2024 was 270.5%. For fiscal 2023 it was -27.7%, against -167.8% the year before. The highest annual figure on record is 4.5% in fiscal 2013.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-27.7%+140.1
FY2022Dec 31, 2022-167.8%−2.9
FY2021Dec 31, 2021-165.0%−49.3
FY2020Dec 31, 2020-115.7%−57.0
FY2019Dec 31, 2019-58.7%+47.3
FY2018Dec 31, 2018-105.9%−48.2
FY2017Dec 31, 2017-57.7%+332.6
FY2016Dec 31, 2016-390.3%+76.3
FY2015Dec 31, 2015-466.6%−332.5
FY2014Dec 31, 2014-134.2%−138.6
FY2013Dec 31, 20134.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2024Mar 31, 2024-3318.9%−2517.7
Q4 FY2023Dec 31, 20231030.5%+1227.5
Q3 FY2023Sep 30, 2023-60.5%+166.1
Q2 FY2023Jun 30, 202310.3%+343.7
Q1 FY2023Mar 31, 2023-801.2%−733.3
Q4 FY2022Dec 31, 2022-197.0%−66.8
Q3 FY2022Sep 30, 2022-226.6%+242.0
Q2 FY2022Jun 30, 2022-333.4%+176.8
Q1 FY2022Mar 31, 2022-67.9%−35.5
Q4 FY2021Dec 31, 2021-130.3%+530.9
Q3 FY2021Sep 30, 2021-468.6%−26.3
Q2 FY2021Jun 30, 2021-510.2%−468.8
Q1 FY2021Mar 31, 2021-32.4%−3.3
Q4 FY2020Dec 31, 2020-661.2%−653.5
Q3 FY2020Sep 30, 2020-442.3%−423.0
Q2 FY2020Jun 30, 2020-41.4%+188.0
Q1 FY2020Mar 31, 2020-29.1%+95.9
Q4 FY2019Dec 31, 2019-7.7%+249.7
Q3 FY2019Sep 30, 2019-19.3%+74.3
Q2 FY2019Jun 30, 2019-229.4%−210.2
Q1 FY2019Mar 31, 2019-125.0%+70.9
Q4 FY2018Dec 31, 2018-257.4%−293.1
Q3 FY2018Sep 30, 2018-93.5%+38.5
Q2 FY2018Jun 30, 2018-19.2%+406.7
Q1 FY2018Mar 31, 2018-196.0%+400.2
Q4 FY2017Dec 31, 201735.7%+270.7
Q3 FY2017Sep 30, 2017-132.0%+655.0
Q2 FY2017Jun 30, 2017-425.8%–
Q1 FY2017Mar 31, 2017-596.1%–
Q4 FY2016Dec 31, 2016-234.9%–
Q3 FY2016Sep 30, 2016-787.0%–

More Palvella Therapeutics figures

See a number that looks wrong?